Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 27

PMID 35887242

Authors

Mariapia Vairetti

Giuseppe Colucci

Andrea Ferrigno

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is among the most common liver diseases worldwide, affecting up to 20-30% of the human population [...].

Citing Articles

Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice.

Cho Y, Kim Y, Kim S, Lee H, Hwang S Int J Mol Sci. 2023; 24(20).

PMID: 37895168 PMC: 10607753. DOI: 10.3390/ijms242015489.

References

Arulkumar R, Jin Jung H, Noh S, Young Chung H . Soyasapogenol C from Fermented Soybean () Acting as a Novel AMPK/PPARα Dual Activator Ameliorates Hepatic Steatosis: A Novel SANDA Methodology. Int J Mol Sci. 2022; 23(10). PMC: 9141180. DOI: 10.3390/ijms23105468. View

Wang C, Liu H, Chang Z, Huang T, Lee T . Losartan Prevents Hepatic Steatosis and Macrophage Polarization by Inhibiting HIF-1α in a Murine Model of NAFLD. Int J Mol Sci. 2021; 22(15). PMC: 8346090. DOI: 10.3390/ijms22157841. View

Salvoza N, Bedin C, Saccani A, Tiribelli C, Rosso N . The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH). Int J Mol Sci. 2022; 23(7). PMC: 8998673. DOI: 10.3390/ijms23073562. View

Salvoza N, Giraudi P, Tiribelli C, Rosso N . Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. Int J Mol Sci. 2022; 23(5). PMC: 8911502. DOI: 10.3390/ijms23052764. View

Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J . The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2021; 22(24). PMC: 8704688. DOI: 10.3390/ijms222413219. View

Yamaguchi T, Yoshida K, Murata M, Suwa K, Tsuneyama K, Matsuzaki K . Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis. Int J Mol Sci. 2022; 23(11). PMC: 9181097. DOI: 10.3390/ijms23116270. View

Wegrzyniak O, Rosestedt M, Eriksson O . Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2021; 22(14). PMC: 8306605. DOI: 10.3390/ijms22147348. View

Yokosaki Y, Nishimichi N . New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, α8β1 and α11β1, Induced Specifically on Activated Stellate Cells. Int J Mol Sci. 2021; 22(23). PMC: 8657911. DOI: 10.3390/ijms222312794. View

Younossi Z, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N . Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2019; 69(3):564-568. DOI: 10.1136/gutjnl-2019-318813. View

10.

Mandala A, Dobrinskikh E, Janssen R, Fiehn O, DAlessandro A, Friedman J . Maternal Pyrroloquinoline Quinone Supplementation Improves Offspring Liver Bioactive Lipid Profiles throughout the Lifespan and Protects against the Development of Adult NAFLD. Int J Mol Sci. 2022; 23(11). PMC: 9181499. DOI: 10.3390/ijms23116043. View

11.

Palladini G, Di Pasqua L, Cagna M, Croce A, Perlini S, Mannucci B . MCD Diet Rat Model Induces Alterations in Zinc and Iron during NAFLD Progression from Steatosis to Steatohepatitis. Int J Mol Sci. 2022; 23(12). PMC: 9224179. DOI: 10.3390/ijms23126817. View

12.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

13.

Caddeo A, Kowalik M, Serra M, Runfola M, Bacci A, Rapposelli S . TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD. Int J Mol Sci. 2021; 22(23). PMC: 8657920. DOI: 10.3390/ijms222313105. View

14.

Brankovic M, Jovanovic I, Dukic M, Radonjic T, Opric S, Klasnja S . Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci. 2022; 23(9). PMC: 9105530. DOI: 10.3390/ijms23095146. View

15.

Hashimoto T, Sugihara T, Kanda T, Takata T, Isomoto H . 5-Aminolevulinic Acid Attenuates Glucose-Regulated Protein 78 Expression and Hepatocyte Lipoapoptosis via Heme Oxygenase-1 Induction. Int J Mol Sci. 2021; 22(21). PMC: 8584191. DOI: 10.3390/ijms222111405. View

16.

Fujisawa K, Takami T, Okubo S, Nishimura Y, Yamada Y, Kondo K . Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose. Int J Mol Sci. 2021; 22(18). PMC: 8467182. DOI: 10.3390/ijms22189931. View

17.

Forlano R, Mullish B, Roberts L, Thursz M, Manousou P . The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2022; 23(2). PMC: 8775587. DOI: 10.3390/ijms23020662. View

18.

Huttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M . In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. Int J Mol Sci. 2021; 22(21). PMC: 8584090. DOI: 10.3390/ijms222111513. View

19.

Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros C, Kyriakopoulos G . Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int J Mol Sci. 2021; 22(2). PMC: 7829901. DOI: 10.3390/ijms22020818. View

20.

Zhang C, Yang M . Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci. 2021; 22(14). PMC: 8306701. DOI: 10.3390/ijms22147571. View